Emerging monitoring technologies in kidney transplantation
Abstract Non-invasive technologies to monitor kidney allograft health utilizing high-throughput assays of blood and urine specimens are emerging out of the research realm and slowly becoming part of everyday clinical practice. HLA epitope analysis and eplet mismatch score determination promise a more refined approach to the pre-transplant recipient–donor HLA matching that may lead to reduced rejection risk. High-resolution HLA typing and multiplex single antigen bead assays are identifying potential new offending HLA antibody subtypes. There is increasing recognition of the deleterious role non-HLA antibodies play in post-transplant outcomes. Donor-derived cell-free DNA detected by next-generation sequencing is a promising biomarker for kidney transplant rejection. Multi-omics techniques are shedding light on discrete genomic, transcriptomic, proteomic, and metabolomic signatures that correlate with and predict allograft outcomes. Over the next decade, a comprehensive approach to optimize kidney matching and monitor transplant recipients for acute and chronic graft dysfunction will likely involve a combination of those emerging technologies summarized in this review..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Pediatric nephrology - 36(2021), 10 vom: 01. Feb., Seite 3077-3087 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ehlayel, Abdulla [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Biomarker |
| Anmerkungen: |
© IPNA 2021 |
|---|
| doi: |
10.1007/s00467-021-04929-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR045089183 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR045089183 | ||
| 003 | DE-627 | ||
| 005 | 20230520000613.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210917s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00467-021-04929-9 |2 doi | |
| 035 | |a (DE-627)SPR045089183 | ||
| 035 | |a (SPR)s00467-021-04929-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.88 |2 bkl | ||
| 084 | |a 44.67 |2 bkl | ||
| 100 | 1 | |a Ehlayel, Abdulla |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emerging monitoring technologies in kidney transplantation |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © IPNA 2021 | ||
| 520 | |a Abstract Non-invasive technologies to monitor kidney allograft health utilizing high-throughput assays of blood and urine specimens are emerging out of the research realm and slowly becoming part of everyday clinical practice. HLA epitope analysis and eplet mismatch score determination promise a more refined approach to the pre-transplant recipient–donor HLA matching that may lead to reduced rejection risk. High-resolution HLA typing and multiplex single antigen bead assays are identifying potential new offending HLA antibody subtypes. There is increasing recognition of the deleterious role non-HLA antibodies play in post-transplant outcomes. Donor-derived cell-free DNA detected by next-generation sequencing is a promising biomarker for kidney transplant rejection. Multi-omics techniques are shedding light on discrete genomic, transcriptomic, proteomic, and metabolomic signatures that correlate with and predict allograft outcomes. Over the next decade, a comprehensive approach to optimize kidney matching and monitor transplant recipients for acute and chronic graft dysfunction will likely involve a combination of those emerging technologies summarized in this review. | ||
| 650 | 4 | |a Biomarker |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Kidney transplant |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Rejection |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Graft dysfunction |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Multi-omics |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Emerging technologies |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Simms, K’joy J. A. |e verfasserin |4 aut | |
| 700 | 1 | |a Ashoor, Isa F. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric nephrology |d Berlin : Springer, 1987 |g 36(2021), 10 vom: 01. Feb., Seite 3077-3087 |w (DE-627)SPR006369421 |w (DE-600)1463004-7 |x 1432-198X |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2021 |g number:10 |g day:01 |g month:02 |g pages:3077-3087 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00467-021-04929-9 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.88 |q ASE |
| 936 | b | k | |a 44.67 |q ASE |
| 951 | |a AR | ||
| 952 | |d 36 |j 2021 |e 10 |b 01 |c 02 |h 3077-3087 | ||